NFKB1 and melanoma: Furthermore, in combination with the hypoglycemic agent metformin, a drug largely used for type 2 diabetes, the EGCG inhibited the NF-kB/STAT3 signaling pathways, resulting in reduced melanoma growth and metastatic potential, and decreased pro-inflammatory mediators such as IL-6, IL-10 and TNF-α [174].